Inotrem announces positive results from the Phase IIa study of its lead compound, nangibotide (LR12), in the treatment of septic shock.
The study demonstrated the safety and tolerability of its lead compound in patients suffering from septic shock Paris, October 1st. 2018. Inotrem S.A., a biotechnology